Pfizer: 2026 Guidance Points To Continued Margin And Growth Pressure

Pfizer's 2026 revenue midpoint of $61B and EPS midpoint of $2.90 decline YoY, reflecting persisting headwinds. Read more on ...

Pfizer collaborating with Boltz to use AI models for drug discovery

Pfizer (PFE) has entered into an agreement with Boltz to use the latter's biomolecular AI foundation models to tap into the ...

Pfizer Turns To AI Where Drug Risk Is Highest

Pfizer is taking a more hands-on approach to AI in drug research, teaming up with startup Boltz to help its scientists make ...

2 Predictions for Pfizer in 2026

Pfizer recently announced its guidance for 2026. One thing seems clear: Its financial results won't get much stronger. It ...

Pfizer (PFE) navigates patent losses with strategic cost controls, BMO Capital reaffirms outperform rating

Pfizer Inc. (NYSE:PFE) ranks among the best stocks under $25 to buy now. Citing the company’s cautious 2026 outlook, BMO ...

Pfizer 2026: The Reset Year

Pfizer enters 2026 facing earnings pressure from COVID revenue collapse and acquisition-related dilution. Click here to read ...
Nasdaq

What Analyst Projections for Key Metrics Reveal About Pfizer (PFE) Q3 Earnings

Wall Street analysts forecast that Pfizer (PFE) will report quarterly earnings of $0.66 per share in its upcoming release, pointing to a year-over-year decline of 37.7%. It is anticipated that ...